ES2687854T3 - Pirazolopiridazinas y métodos para tratar las enfermedades degenerativas de la retina y la pérdida de audición asociada con el síndrome de Usher - Google Patents

Pirazolopiridazinas y métodos para tratar las enfermedades degenerativas de la retina y la pérdida de audición asociada con el síndrome de Usher Download PDF

Info

Publication number
ES2687854T3
ES2687854T3 ES13848995.0T ES13848995T ES2687854T3 ES 2687854 T3 ES2687854 T3 ES 2687854T3 ES 13848995 T ES13848995 T ES 13848995T ES 2687854 T3 ES2687854 T3 ES 2687854T3
Authority
ES
Spain
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
usher
syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13848995.0T
Other languages
English (en)
Spanish (es)
Inventor
Roland Werner BURLI
William Rameshchandra Krishna ESMIEU
Christopher James Lock
Karine Fabienne MALAGU
Andrew Pate Owens
William Edward HARTE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Usher III Initiative
Original Assignee
Usher III Initiative
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Usher III Initiative filed Critical Usher III Initiative
Application granted granted Critical
Publication of ES2687854T3 publication Critical patent/ES2687854T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ES13848995.0T 2012-10-25 2013-10-25 Pirazolopiridazinas y métodos para tratar las enfermedades degenerativas de la retina y la pérdida de audición asociada con el síndrome de Usher Active ES2687854T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261718611P 2012-10-25 2012-10-25
US201261718611P 2012-10-25
US201361775402P 2013-03-08 2013-03-08
US201361775402P 2013-03-08
PCT/US2013/066939 WO2014066836A1 (en) 2012-10-25 2013-10-25 Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome

Publications (1)

Publication Number Publication Date
ES2687854T3 true ES2687854T3 (es) 2018-10-29

Family

ID=50545356

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13848995.0T Active ES2687854T3 (es) 2012-10-25 2013-10-25 Pirazolopiridazinas y métodos para tratar las enfermedades degenerativas de la retina y la pérdida de audición asociada con el síndrome de Usher

Country Status (10)

Country Link
EP (1) EP2911671B1 (enExample)
JP (1) JP6291502B2 (enExample)
AU (1) AU2013334139B2 (enExample)
CA (1) CA2889494C (enExample)
ES (1) ES2687854T3 (enExample)
HU (1) HUE039970T2 (enExample)
IL (1) IL238288B (enExample)
PL (1) PL2911671T3 (enExample)
WO (1) WO2014066836A1 (enExample)
ZA (1) ZA201502655B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5902293B2 (ja) 2011-04-25 2016-04-13 アッシャー・サード・イニシアティブ・インコーポレイテッド ピラゾロピリダジンおよび網膜変性疾患およびアッシャー症候群に伴う聴覚損失を治療するための方法
US9227976B2 (en) 2012-10-25 2016-01-05 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
JP6290910B2 (ja) * 2012-10-25 2018-03-07 アッシャー・サード・イニシアティブ・インコーポレイテッド ピラゾロピリダジンならびに網膜変性疾患およびアッシャー症候群に伴う聴力損失を処置するための方法
WO2017045955A1 (en) * 2015-09-14 2017-03-23 Basf Se Heterobicyclic compounds
EP4151627A1 (en) 2017-06-05 2023-03-22 PTC Therapeutics, Inc. Compounds for treating huntington's disease
BR112020019373A2 (pt) 2018-03-27 2020-12-29 Ptc Therapeutics, Inc. Compostos para o tratamento da doença de hutington
KR20210038845A (ko) 2018-06-27 2021-04-08 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료를 위한 헤테로아릴 화합물
IL279688B2 (en) * 2018-06-27 2025-01-01 Ptc Therapeutics Inc Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease
WO2020161208A1 (en) 2019-02-06 2020-08-13 Syngenta Crop Protection Ag Herbicidal fused pyridazine compounds
WO2020161209A1 (en) 2019-02-06 2020-08-13 Syngenta Crop Protection Ag Herbicidal fused pyridazine compounds
CA3139821A1 (en) 2019-05-13 2020-11-19 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
EP4178580B1 (en) 2020-07-09 2025-11-05 Usher III Initiative, Inc. Bf 844 for use in the treatment of cancer
WO2023139091A1 (en) * 2022-01-19 2023-07-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Geralexin and uses thereof for the treatment of retinal degenerative diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206723D0 (en) * 2002-03-21 2002-05-01 Glaxo Group Ltd Novel compounds
US20090306045A1 (en) * 2005-12-22 2009-12-10 Ira Mellman Inhibition of Glycogen Synthase Kinase and Methods of Treating Autoimmune or Immune Inflammatory Disease
WO2009062118A2 (en) * 2007-11-07 2009-05-14 Foldrx Pharmaceuticals, Inc. Modulation of protein trafficking
JP5902293B2 (ja) * 2011-04-25 2016-04-13 アッシャー・サード・イニシアティブ・インコーポレイテッド ピラゾロピリダジンおよび網膜変性疾患およびアッシャー症候群に伴う聴覚損失を治療するための方法
JP6290910B2 (ja) * 2012-10-25 2018-03-07 アッシャー・サード・イニシアティブ・インコーポレイテッド ピラゾロピリダジンならびに網膜変性疾患およびアッシャー症候群に伴う聴力損失を処置するための方法

Also Published As

Publication number Publication date
AU2013334139B2 (en) 2017-08-03
EP2911671B1 (en) 2018-06-27
PL2911671T3 (pl) 2018-11-30
HK1214180A1 (en) 2016-07-22
IL238288B (en) 2018-04-30
CA2889494C (en) 2018-12-18
ZA201502655B (en) 2017-11-29
IL238288A0 (en) 2015-06-30
AU2013334139A1 (en) 2015-04-30
JP2015535257A (ja) 2015-12-10
EP2911671A4 (en) 2016-09-14
CA2889494A1 (en) 2014-05-01
WO2014066836A1 (en) 2014-05-01
EP2911671A1 (en) 2015-09-02
HUE039970T2 (hu) 2019-02-28
JP6291502B2 (ja) 2018-03-14

Similar Documents

Publication Publication Date Title
ES2625534T3 (es) Pirazolopiridazinas y métodos para el tratamiento de enfermedades degenerativas de la retina y pérdida de la audición asociadas con el síndrome de Usher
WO2019209955A3 (en) Use of pilocarpine hydrochloride for the treatment of ocular conditions
EA201300272A1 (ru) Применение фотоусиливающих агентов в ассоциации с рибофлавином, а также соответствующих офтальмологических композиций для перекрестного сшивания роговицы при лечении кератоконуса или других эктазийных расстройств роговицы
WO2017158365A3 (en) Ophthalmic delivery device and ophthalmic active agent containing compositions
PH12015502587A1 (en) Opthalmic nanoemulsion composition containing cyclosporine and method for preparing same
Kordić et al. Application of the amniotic membrane extract (AMX) for the persistent epithelial defect (PED) of the cornea
EA200800337A1 (ru) Композиция и способ введения офтальмологически активных средств
EP4410312A3 (en) Topical cyclosporine-containing formulations and uses thereof
MX2021016055A (es) Formulaciones y métodos de parasiticidas de isoxazolina para el tratamiento de la blefaritis.
ES2693166T3 (es) Pirazolopiridina y métodos para tratar las enfermedades retinales degenerativas y la pérdida auditiva asociadas con el síndrome de Usher
MX2022005063A (es) Tratamiento de enfermedades oculares con antagonistas de receptor de endotelina.
Kim et al. In vitro effects of preservative-free and preserved prostaglandin analogs on primary cultured human conjunctival fibroblast cells
AR045943A1 (es) Formulaciones de acetonido de triamcinolona y acetato de anecortave para inyeccion
MX2021008821A (es) Derivados de bis (diazirina) como foto-reticulante para el tratamiento de trastornos ectasicos de cornea.
CA3062744A1 (en) Neurotrophins for use in the treatment of hearing loss
WO2005105133A3 (en) Methods and compositions for preserving the viability of photoreceptor cells
DOP2003000747A (es) Composiciones oftalmicas para el tratamiento de la hipertension ocular
ATE412402T1 (de) Ophthalmische suspension aus einem ophthalmischen arzneimittel, einem poloxamin und glykol- tonizitätsanpassenden mittel, verwendung der zusammensetzung zur herstellung eines medikaments zur behandlung von augenerkrankungen
CN108137595A (zh) 预防和治疗听力损失的方法和组合物
Leong et al. Serious complications during aural impression-taking for hearing aids: a case report and review of the literature
Bakir et al. Histopathologic results of long-term sildenafil administration on rat inner ear
Qadir et al. Age-Related Hearing Loss: A Review of a Hot Topic in Audiology
WO2007019427A3 (en) Methods and compositions for preserving the viability of photoreceptor cells
Sarnicola et al. Recent developments in cornea and corneal transplants
Ward et al. Case report: suspected donor transmission of Acanthamoeba keratitis after deep anterior lamellar keratoplasty